Five Star Quality Care, Inc(FVE) is a national healthcare and senior living provider, offers the highest quality of care and service. Five Star has two major operating divisions: Five Star Senior Living and Five Star Rehabilitation Services. The Five Star Senior…
Tag: biopharma catalyst trading
BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
These days, prescription drugs have become a source for legal and illegal abuse. This abuse can lead to a medical diagnosis called opioid dependence, which is when a patient that is addicted to opioids such as morphine, hydrocodone, oxycodone, or…
Mannkind Thesis – Bearish $MNKD
In my opinion, investors need to be careful of the current MNKD stock run up. It’s likely it’s manipulation being pulled off by the warrant holders in order for them to cash out with good profit. Company has ZERO chance…
Biosciences Delivery Systems+ Antares Chart Update: 5/25/13 $BDSI, $ATRS
My opinion on Antares BDSI pasy trading action and for the future.
I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.
BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. …
I bought Antares @ $3.95, I see a move to $4.35 short term
I bought Antares @ $3.95, I see a move to $4.35 short term. I think from tomorrow to beginning of next week, we see the move. From above, we can clearly see a tightening wedge forming in the chart. I…
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
